Publications

Dernière publication 28/02/2022

Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic S

Ischemic stroke is a primary cause of morbidity and mortality worldwide. Beyond the approved thrombolytic therapies, there is no effective...

Array
(
    [id_prestablog_news] => 1520
    [id_shop] => 1
    [date] => 2022-02-28 00:00:00
    [date_modification] => 2024-02-09 14:15:13
    [langues] => ["1","2"]
    [actif] => 1
    [slide] => 0
    [url_redirect] => 
    [average_rating] => 
    [number_rating] => 
    [author_id] => 1
    [featured] => 0
    [prim_key] => 3252
    [id_lang] => 2
    [title] => Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic S
    [paragraph] => Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke
    [content] => 
Authors
A Simats, L Ramiro, R Valls et al

 Lab
Universitat Autonoma de Barcelona, Hospital Universitari Vall dÕHebron, Barcelona, Spain
Journal
Neurotherapeutics
Abstract
Ischemic stroke is a primary cause of morbidity and mortality worldwide. Beyond the approved thrombolytic therapies, there is no effective treatment to mitigate its progression. Drug repositioning combinational therapies are becoming promising approaches to identify new uses of existing drugs to synergically target multiple disease-response mechanisms underlying complex pathologies. Here, we used a systems biologyÐbased approach based on artificial intelligence and pattern recognition tools to generate in silico mathematical models mimicking the ischemic stroke pathology. Combinational treatments were acquired by screening these models with more than 5 million two-by-two combinations of drugs. A drug combination (CA) formed by ceruletide and alpha-1 antitrypsin showing a predicted value of neuroprotection of 92% was evaluated for their synergic neuroprotective effects in a mouse pre-clinical stroke model. The administration of both drugs in combination was safe and effective in reducing by 39.42% the infarct volume 24 h after cerebral ischemia. This neuroprotection was not observed when drugs were given individually. Importantly, potential incompatibilities of the drug combination with tPA thrombolysis were discarded in vitro and in vivo by using a mouse thromboembolic stroke model with t-PA-induced reperfusion, revealing an improvement in the forepaw strength 72 h after stroke in CA-treated mice. Finally, we identified the predicted mechanisms of action of ceruletide and alpha-1 antitrypsin and we demonstrated that CA modulates EGFR and ANGPT-1 levels in circulation within the acute phase after stroke. In conclusion, we have identified a promising combinational treatment with neuroprotective effects for the treatment of ischemic stroke.
BIOSEB Instruments Used
Grip strength test (BIO-GS3)
    [meta_description] => 
    [meta_keywords] => https://doi.org/10.1007/s13311-022-01203-0
    [meta_title] => 
    [link_rewrite] => ceruletide-and-alpha-1-antitrypsin-as-a-novel-combination-therapy-for-ischemic-stroke
    [actif_langue] => 1
    [read] => 810
    [count_comments] => 0
    [id] => 1520
    [categories] => Array
        (
            [40] => Array
                (
                    [id_prestablog_categorie] => 40
                    [title] => Accidents ischémiques transitoires (AIT)
                    [link_rewrite] => Accidents-ischemiques-transitoires-AIT
                )

            [2] => Array
                (
                    [id_prestablog_categorie] => 2
                    [title] => Publications
                    [link_rewrite] => publications
                )

        )

    [authors] => 
    [paragraph_crop] => Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke
    [link_for_unique] => 1
    [products_liaison] => Array
        (
            [48] => Array
                (
                    [name] => Test d'agrippement
                    [description_short] => 
Une méthode simple pour quantifier objectivement la force musculaire des rats et souris et l'effet de drogues, toxines, maladies musculaires (ex: myopathie) et neurodégénératives. Cette mesure de force est souvent employée en association avec le test de coordination motrice ROTAROD: un sujet présentant une coordination normale montrera des résultats médiocres en cas de faible force musculaire. Un must pour vos recherches sur l'activité, la coordination et le contrôle musculaire: particulièrement utile pour vos études sur les maladies de Parkinson et Huntington.
Nouveautés GS4 - 2023: Écran couleur rétroéclairé (meilleure lisibilité), pédale de remise à zéro, durée de batterie optimisée, taille de mémoire augmentée à 500 valeurs, compteur d'animaux, port USB (transfert de données/charge)

                    [thumb] => 
                    [img_empty] => /var/www/vhosts/de3310.ispfr.net/preprod.bioseb.com/modules/prestablog/views/img/product_link_white.jpg
                    [image_presente] => 1
                    [link] => https://preprod.bioseb.com/fr/activite-systeme-moteur-coordination/48-grip-strength-test.html
                )

        )

)
1